Acyl glucuronide drug metabolites: Toxicological and analytical implications

Therapeutic Drug Monitoring

Volumn 25, Issue 1, 2003, Pages 1-16

  Shipkova, Maria ^a   Armstrong, Victor William ^a   Oellerich, Michael ^a   Wieland, Eberhard ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Acyl glucuronides; Drug toxicity; Drug protein adducts

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; AMINOSALICYLIC ACID; BECLOBRINIC ACID; BENOXAPROFEN; BUMETANIDE; CARBOXYLIC ACID; CARPROFEN; CLOFIBRATE; CLOFIBRIC ACID; DICLOFENAC; DIFLUNISAL; DRUG METABOLITE; FENOPROFEN; FLUNOXAPROFEN; FUROSEMIDE; GEMFIBROZIL; GLUCURONIDE; IBUPROFEN; INDOMETACIN; KETOPROFEN; MEFENAMIC ACID; MYCOPHENOLIC ACID; NAPROXEN; NUCLEIC ACID; PLASMA PROTEIN; TOLMETIN; VALPROIC ACID; ZOMEPIRAC;

BLOOD ANALYSIS; CHEMICAL BINDING; CHEMICAL MODIFICATION; CHEMICAL REACTION; CHROMATOGRAPHY; CONJUGATION; DRUG DETOXIFICATION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG MONITORING; ELECTROPHORESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HYDROLYSIS; HYPERSENSITIVITY; INFORMATION PROCESSING; METABOLITE; MOLECULAR DYNAMICS; PH; PH MEASUREMENT; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RELIABILITY; REVIEW; TEMPERATURE MEASUREMENT; TOXICOLOGY;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 0037306174     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200302000-00001     Document Type: Review

References (160)

1. Pasternak GW, Bodnar RJ, Clark JA, et al. Morphine-6-glucuronide, a potent mu agonist. Life Sci 1987;41:2845-9.
2. Portenoy RK, Thaler HT, Inturrisi CE, et al. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin Pharmacol Ther 1992;51:422-31.
3. Scholz H, Schmitz W. Positive inotropic effects of digitoxin- and digoxin-glucuronide in human isolated ventricular heart muscle preparations. Basic Res Cardiol 1984;79(suppl):134-9.
4. Arakawa M, Shimizu F, Sasagawa K, et al. Antitumor activity of methyl (5-fluoro-1H-2-oxo-4-pyrimidinyl beta-D-glucopyranosid)uronate against various experimental tumors. Gann 1981;72:220-5.
5. Shipkova M, Wieland E, Schütz E, et al. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc 2001;33:1080-1.
6. Ritter JK. Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem Biol Interact 2000;129:171-93.
7. Spahn-Langguth H, Dahms M, Hermening A. Acyl glucuronides: covalent binding and its potential relevance. Adv Exp Med Biol 1996;387:313-28.
8. Faed EM. Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab Rev 1984;15:1213-49.
9. Spahn-Langguth H, Benet LZ. Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 1992;24:5-47.
10. Zia-Amirhosseini P, Spahn-Langguth H, Benet LZ. Bioactivation by glucuronide-conjugate formation. Adv Pharmacol 1994;27:385-97.
11. Boelsterli UA, Zimmerman HJ, Kretz-Rommel A. Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology. Crit Rev Toxicol 1995;25:207-35.
12. Sallustio BC, Sabordo L, Evans AM, et al. Hepatic disposition of electrophilic acyl glucuronide conjugates. Curr Drug Metab 2000;1:163-80.
13. Illing HP, Wilson ID. pH dependent formation of beta-glucuronidase resistant conjugates from the biosynthetic ester glucuronide of isoxepac. Biochem Pharmacol 1981;30:3381-4.
14. Sallustio BC, Fairchild BA, Pannall PR. Interaction of human serum albumin with the electrophilic metabolite 1-O-gemfibrozilbeta-D-glucuronide. Drug Metab Dispos 1997;25:55-60.
15. Williams AM, Dickinson RG. Studies on the reactivity of acyl glucuronides-VI. Modulation of reversible and covalent interaction of diflunisal acyl glucuronide and its isomers with human plasma protein in vitro. Biochem Pharmacol 1994;47:457-67.
16. Wells DS, Janssen FW, Ruelius HW. Interactions between oxaprozin glucuronide and human serum albumin. Xenobiotica 1987;17:1437-49.
17. Munafo A, McDonagh AF, Smith PC, et al. Irreversible binding of tolmetin glucuronic acid esters to albumin in vitro. Pharm Res 1990;7:21-7.
18. Brunelle FM, Verbeeck RK. Conjugation-deconjugation cycling of diflunisal via beta-glucuronidase catalyzed hydrolysis of its acyl glucuronide in the rat. Life Sci 1997;60:2013-21.
19. Smith PC, McDonagh AF, Benet LZ. Effect of esterase inhibition on the disposition of zomepirac glucuronide and its covalent binding to plasma proteins in the guinea pig. J Pharmacol Exp Ther 1990;252:218-24.
20. Rowe BJ, Meffin PJ. Diisopropylfluorophosphate increases clofibric acid clearance: supporting evidence for a futile cycle. J Pharmacol Exp Ther 1984;230:237-41.
21. Dahms M, Spahn-Langguth H. Covalent binding of acidic drugs via reactive intermediates: detection of benoxaprofen and flunoxaprofen protein adducts in biologic material. Pharmazie 1996;51:874-81.
22. Hasegawa J, Smith PC, Benet LZ. Apparent intramolecular acyl migration of zomepirac glucuronide. Drug Metab Dispos 1982;10:469-73.
23. Benet LZ, Spahn-Langguth H, Iwakawa S, et al. Predictability of the covalent binding of acidic drugs in man. Life Sci 1993;53: PL141-6.
24. van Breemen RB, Fenselau C. Acylation of albumin by 1-O-acyl glucuronides. Drug Metab Dispos 1985;13:318-20.
25. Ruelius HW, Kirkman SK, Young EM, et al. Reactions of oxaprozin-1-O-acyl glucuronide in solutions of human plasma and albumin. Adv Exp Med Biol 1986;197:431-41.
26. Ding A, Zia-Amirhosseini P, McDonagh AF, et al. Reactivity of tolmetin glucuronide with human serum albumin. Identification of binding sites and mechanisms of reaction by tandem mass spectrometry. Drug Metab Dispos 1995;23:369-76.
27. Stogniew M, Fenselau C. Electrophilic reactions of acyl-linked glucuronides. Formation of clofibrate mercapturate in humans. Drug Metab Dispos 1982;10:609-13.
28. Shore LJ, Fenselau C, King AR, et al. Characterization and formation of the glutathione conjugate of clofibric acid. Drug Metab Dispos 1995;23:119-23.
29. Smith PC, Benet LZ, McDonagh AF. Covalent binding of zomepirac glucuronide to proteins: evidence for a Schiff base mechanism. Drug Metab Dispos 1990;18:639-44.
30. Smith PC, Liu JH. Covalent binding of suprofen acyl glucuronide to albumin in vitro. Xenobiotica 1993;23:337-48.
31. Kretz-Rommel A, Boelsterli UA. Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins. Retention of the glucuronic acid moiety in the adduct. Drug Metab Dispos 1994;22:956-61.
32. Ding A, Ojingwa JC, McDonagh AF, et al. Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry. Proc Natl Acad Sci U S A 1993;90:3797-801.
33. Grubb N, Weil A, Caldwell J. Studies on the in vitro reactivity of clofibryl and fenofibryl glucuronides. Evidence for protein binding via a Schiff's base mechanism. Biochem Pharmacol 1993;46:357-64.
34. Wang M, Dickinson RG. Disposition and covalent binding of diflunisal and diflunisal acyl glucuronide in the isolated perfused rat liver. Drug Metab Dispos 1998;26:98-104.
35. Smith PC, McDonagh AF, Benet LZ. Irreversible binding of zomepirac to plasma protein in vitro and in vivo. J Clin Invest 1986;77:934-9.
36. Bailey MJ, Dickinson RG. Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma. Chem Res Toxicol 1996;9:659-66.
37. Dickinson RG, Baker PV, King AR. Studies oncthe reactivity of acyl glucuronides-VII. Salicyl acyl glucuronide reactivity in vitro and covalent binding of salicylic acid to plasma protein of humans taking aspirin. Biochem Pharmacol 1994;47:469-76.
38. McGurk KA, Remmel RP, Hosagrahara VP, et al. Reactivity of mefenamic acid 1-o-acyl glucuronide with proteins in vitro and ex vivo. Drug Metab Dispos 1996;24:842-9.
39. Williams AM, Worrall S, de Jersey J, et al. Studies on the reactivity of acyl glucuronides-III. Glucuronide-derived adducts of valproic acid and plasma protein and anti-adduct antibodies in humans. Biochem Pharmacol 1992;43:745-55.
40. Liu JH, Malone RS, Stallings H, et al. Influence of renal failure in rats on the disposition of salicyl acyl glucuronide and covalent binding of salicylate to plasma proteins. J Pharmacol Exp Ther 1996;278:277-83.
41. Dubois N, Lapicque F, Maurice MH, et al. In vitro irreversible binding of ketoprofen glucuronide to plasma proteins. Drug Metab Dispos 1993;21:617-23.
42. Qiu Y, Burlingame AL, Benet LZ. Mechanisms for covalent binding of benoxaprofen glucuronide to human serum albumin. Studies by tandem mass spectrometry. Drug Metab Dispos 1998;26:246-56.
43. Sallustio BC, Knights KM, Roberts BJ, et al. In vivo covalent binding of clofibric acid to human plasma proteins and rat liver proteins. Biochem Pharmacol 1991;42:1421-5.
44. Dickinson RG, King AR. Studies on the reactivity of acyl glucuronides-V. Glucuronide-derived covalent binding of diflunisal to bladder tissue of rats and its modulation by urinary pH and beta-glucuronidase. Biochem Pharmacol 1993;46:1175-82.
45. King AR, Dickinson RG. Studies on the reactivity of acyl glucuronides-IV. Covalent binding of diflunisal to tissues of the rat. Biochem Pharmacol 1993;45:1043-7.
46. Williams AM, Worrall S, De Jersey J, et al. Studies on the reactivity of acyl glucuronides-VIII. Generation of an antiserum for the detection of diflunisal-modified proteins in diflunisal-dosed rats. Biochem Pharmacol 1995;49:209-17.
47. Kretz-Rommel A, Boelsterli UA. Selective protein adducts to membrane proteins in cultured rat hepatocytes exposed to diclofenac: radiochemical and immunochemical analysis. Mol Pharmacol 1994;45:237-44.
48. Kretz-Rommel A, Boelsterli UA. Liver, lung, and spleen as target tissues for protein adduct formation associated with metabolism of the nonsteroidal antiinflammatory drug diclofenac. Toxicologist 1994;14:425.
49. Ojingwa JC, Spahn-Langguth H, Benet LZ. Irreversible binding of tolmetin to macromolecules via its glucuronide: binding to blood constituents, tissue homogenates and subcellular fractions in vitro. Xenobiotica 1994;24:495-506.
50. Hargus SJ, Martin BM, George JW, et al. Covalent modification of rat liver dipeptidyl peptidase IV (CD26) by the nonsteroidal anti-inflammatory drug diclofenac. Chem Res Toxicol 1995;8:993-6.
51. Hargus SJ, Amouzedeh HR, Pumford NR, et al. Metabolic activation and immunochemical localization of liver protein adducts of the nonsteroidal anti-inflammatory drug diclofenac. Chem Res Toxicol 1994;7:575-82.
52. Gil ML, Ramirez MC, Terencio MC, et al. Immunochemical detection of protein adducts in cultured human hepatocytes exposed to diclofenac. Biochim Biophys Acta 1995;1272:140-6.
53. Wade LT, Kenna JG, Caldwell J. Immunochemical identification of mouse hepatic protein adducts derived from the nonsteroidal anti-inflammatory drugs diclofenac, sulindac, and ibuprofen. Chem Res Toxicol 1997;10:546-55.
54. Hertz R, Bar-Tana J. The acylation of proteins by xenobiotic amphipathic carboxylic acids in cultured rat hepatocytes. Biochem J 1988;254:39-44.
55. Pumford NR, Myers TG, Davila JC, et al. Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac. Chem Res Toxicol 1993;6:147-50.
56. Ware JA, Graf ML, Martin BM, et al. Immunochemical detection and identification of protein adducts of diclofenac in the small intestine of rats: possible role in allergic reactions. Chem Res Toxicol 1998;11:164-71.
57. Bailey MJ, Worrall S, de Jersey J. et al. Zomepirac acyl glucuronide covalently modifies tubulin in vitro and in vivo and inhibits its assembly in an in vitro system. Chem Biol Interact 1998;115:153-66.
58. Terrier N, Benoit E, Senay C, et al. Human and rat liver UDP-glucuronosyltransferases are targets of ketoprofen acylglucuronide. Mol Pharmacol 1999;56:226-34.
59. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000;40:581-616.
60. Radominska-Pandya A, Czernik PJ, Little JM, et al. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 1999;31:817-99.
61. Mackenzie PI. Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. Ther Drug Monit 2000;22:10-3.
62. King C, Tang W, Ngui J, et al. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 2001;61:49-53.
63. Jin C, Miners JO, Lillywhite KJ, et al. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther 1993;264:475-9.
64. Radominska-Pandya A, Little JM, Czernik PJ. Human UDP-glucuronosyltransferase 2B7. Curr Drug Metab 2001;2:283-98.
65. Jedlitschky G, Cassidy AJ, Sales M, et al. Cloning and characterization of a novel human olfactory UDP-glucuronosyltransferase. Biochem J 1999;340:837-43.
66. Ebner T, Burchell B. Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab Dispos 1993;21:50-5.
67. Green MD, King CD, Mojarrabi B, et al. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos 1998;26:507-12.
68. Strassburg CP, Oldhafer K, Manns MP, et al. Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A1O transcripts in extrahepatic tissue. Mol Pharmacol 1997;52:212-20.
69. Strassburg CP, Manns MP, Tukey RH. Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem 1998;273:8719-26.
70. Dragacci S, Hamar-Hansen C, Foumel-Gigleux S, et al. Comparative study of clofibric acid and bilirubin glucuronidation in human liver microsomes. Biochem Pharmacol 1987;36:3923-7.
71. Shipkova M, Strassburg CP, Braun F, et al. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 2001;132:1027-34.
72. Burchell B, Coughtrie MW. Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation. Environ Health Perspect 1997;105(suppl 4):739-47.
73. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999;43(suppl B):83-90.
74. Castillo M, Lam YW, Dooley MA, et al. Disposition and covalent binding of ibuprofen and its acyl glucuronide in the elderly. Clin Pharmacol Ther 1995;57:636-44.
75. Shipkova M, Armstrong VW, Weber L, et al. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 2002;24:390-9.
76. Zhou SF, Paxton JW, Tingle MD, et al. Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans. Xenobiotica 2001;31:277-93.
77. Gugler R, Kurten JW, Jensen CJ, et al. Clofibrate disposition in renal failure and acute and chronic liver disease. Eur J Clin Pharmacol 1979;15:341-7.
78. Smith PC, Langendijk PN, Bosso JA, et al. Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac. Clin Pharmacol Ther 1985;38:121-7.
79. Grubb NG, Rudy DW, Brater DC, et al. Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a "futile cycle" of elimination. Br J Clin Pharmacol 1999;48:494-500.
80. Sallustio BC, Purdie YJ, Birkett DJ, et al. Effect of renal dysfunction on the individual components of the acyl-glucuronide futile cycle. J Pharmacol Exp Ther 1989;251:288-94.
81. Hayball PJ, Nation RL, Bochner F, et al. The influence of renal function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol 1993;36:185-93.
82. Aronoff GR, Ozawa T, DeSante KA, et al. Benoxaprofen kinetics in renal impairment. Clin Pharmacol Ther 1982;32:190-4.
83. Meffin PJ, Zilm DM, Veenendaal JR. Reduced clofibric acid clearance in renal dysfunction is due to a futile cycle. J Pharmacol Exp Ther 1983;227:732-8.
84. Dickinson RG, Verbeeck RK, King AR, et al. Diflunisal and its conjugates in patients with renal failure. Br J Clin Pharmacol 1991;31:546-50.
85. Verbeeck RK, Wallace SM, Loewen GR. Reduced elimination of ketoprofen in the elderly is not necessarily due to impaired glucuronidation. Br J Clin Pharmacol 1984;17:783-4.
86. Stein G, Kunze M, Zaumseil J, et al. Pharmacokinetics of indomethacin and indomethacin metabolites administered continuously to patients with healthy or damaged kidneys. Int J Clin Pharmacol Biopharm 1977;15:470-3.
87. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1998;9:1511-20.
88. Zia-Amirhosseini P, Ojingwa JC, Spahn-Langguth H, et al. Enhanced covalent binding of tolmetin to proteins in humans after multiple dosing. Clin Pharmacol Ther 1994;55:21-7.
89. Mayer S, Mutschler E, Benet LZ, et al. In vitro and in vivo irreversible plasma protein binding of beclobric acid enantiomers. Chirality 1993;5:120-5.
90. Meech R, Mackenzie PI. Structure and function of uridine diphosphate glucuronosyltransferases. Clin Exp Pharmacol Physiol 1997;24:907-15.
91. Hirom PC, Millburn P, Smith RL. Bile and urine as complementary pathways for the excretion of foreign organic compounds. Xenobiotica 1976;6:55-64.
92. Vore M. Canalicular transport: discovery of ATP-dependent mechanisms. Toxicol Appl Pharmacol 1993;118:2-7.
93. Knauf H, Kolle EU, Mutschler E. Gemfibrozil absorption and elimination in kidney and liver disease. Klin Wochenschr 1990;68:692-8.
94. Stierlin H, Faigle JW. Biotransformation of diclofenac sodium (Voltaren) in animals and in man. II. Quantitative determination of the unchanged drug and principal phenolic metabolites, in urine and bile. Xenobiotica 1979;9:611-21.
95. Schneider HT, Nuemberg B, Dietzel K, et al. Biliary elimination of non-steroidal anti-inflammatory drugs in patients. Br J Clin Pharmacol 1990;29:127-31.
96. Dickinson RG, King AR. Rearrangement of diflunisal acyl glucuronide into its beta-glucuronidase-resistant isomers facilitates transport through the small intestine to the colon of the rat. Life Sci 2001;70:25-36.
97. Spahn H, Spahn I, Benet LZ. Probenecid-induced changes in the clearance of carprofen enantiomers: a preliminary study. Clin Pharmacol Ther 1989;45:500-5.
98. Hyneck ML, Smith PC, Munafo A, et al. Disposition and irreversible plasma protein binding of tolmetin in humans. Clin Pharmacol Ther 1988;44:107-14.
99. Vree TB, Van Den Biggelaar-Martea M, Verwey-Van Wissen CP, et al. The pharmacokinetics of naproxen, its metabolite Odesmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. Br J Clin Pharmacol 1993;35:467-72.
100. Chatfield DH, Green JN. Disposition and metabolism of benoxaprofen in laboratory animals and man. Xenobiotica 1978;8:133-44.
101. Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34:429-55.
102. Brunelle FM, Verbeeck RK. Glucuronidation of diflunisal in liver and kidney microsomes of rat and man. Xenobiotica 1996;26:123-31.
103. McGurk KA, Brierley CH, Burchell B. Drug glucuronidation by human renal UDP-glucuronosyltransferases. Biochem Pharmacol 1998;55:1005-12.
104. Vree TB, Van Ewijk-Beneken Kolmer EW, Wuis EW, et al. Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans. Pharm World Sci 1993;15:197-202.
105. Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CP. Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. Br J Clin Pharmacol 1995;39:692-5.
106. Vree TB, van der Ven AJ. Clinical consequences of the biphasic elimination kinetics for the diuretic effect of furosemide and its acyl glucuronide in humans. J Pharm Pharmacol 1999;51:239-48.
107. Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CP, et al. Probenecid inhibits the glucuronidation of indomethacin and O-desmethylindomethacin in humans. A pilot experiment. Pharm World Sci 1994;16:22-6.
108. Vree TB, Van den Biggelaar-Martea M, Van Ewijk-Beneken Kolmer EW, et al. Probenecid inhibits the renal clearance and renal glucuronidation of nalidixic acid. A pilot experiment. Pharm World Sci 1993;15:165-70.
109. Smith PC, Liu JH. Covalent binding of suprofen to renal tissue of rat correlates with excretion of its acyl glucuronide. Xenobiotica 1995;25:531-40.
110. Ott RJ, Giacomini KM. Stereoselective transport of drugs across epithelia. In: Wainer IW, ed. Drug stereochemistry: analytical methods and pharmacology. New York: Marcel Dekker Inc., 1993:281-314.
111. Sallustio BC, Fairchild BA, Shanahan K, et al. Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. Drug Metab Dispos 1996;24:984-9.
112. Sabordo L, Sallustio BC, Evans AM, et al. Hepatic disposition of the acyl glucuronide1-O-gemfibrozil-beta-D-glucuronide: effects of dibromosulfophthalein on membrane transport and aglycone formation. J Pharmacol Exp Ther 1999;288:414-20.
113. Sabordo L, Sallustio BC, Evans AM, et al. Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil-beta-D-glucuronide: effects of clofibric acid, acetaminophen, and acetaminophen glucuronide. J Pharmacol Exp Ther 2000;295:44-50.
114. Seitz S, Kretz-Rommel A, Oude Elferink RP, et al. Selective protein adduct formation of diclofenac glucuronide is critically dependent on the rat canalicular conjugate export pump (Mrp2). Chem Res Toxicol 1998;11:513-9.
115. Kamisako T, Leier I, Cui Y, et al. Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology 1999;30:485-90.
116. Shipkova M, Armstrong VW, Kuypers D, et al. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther Drug Monit 2001;23:717-21.
117. Pumford NR, Halmes NC, Hinson JA. Covalent binding of xenobiotics to specific proteins in the liver. Drug Metab Rev 1997;29:39-57.
118. Chiou YJ, Tomer KB, Smith PC. Effect of nonenzymatic glycation of albumin and superoxide dismutase by glucuronic acid and suprofen acyl glucuronide on their functions in vitro. Chem Biol Interact 1999;121:141-59.
119. Wang M, Gorrell MD, McGaughan GW, et al. Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac. Life Sci 2001;68:785-97.
120. Sallustio BC, Harkin LA, Mann MC, et al. Genotoxicity of acyl glucuronide metabolites formed from clofibric acid and gemfibrozil: a novel role for phase-II-mediated bioactivation in the hepatocarcinogenicity of the parent aglycones? Toxicol Appl Pharmacol 1997;147:459-64.
121. Cannell GR, Vesey DA, Dickinson RG. Inhibition of proliferation of HT-29 colon adenocarcinoma cells by carboxylate NSAIDs and their acyl glucuronides. Life Sci 2001;70:37-48.
122. Wieland E, Shipkova M, Schellhaas U, et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 2000;33:107-13.
123. Wieland E, Shipkova M, Armstrong VW, et al. Effect of mycophenolic acid and its glucuronide metabolites on MCP-1 and ICAM-1 gene expression in human mononuclear leukocytes. [Abstract]. Ther Drug Monit 2001;23:475.
124. Seitz S, Boelsterli UA. Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats. Gastroenterology 1998;115:1476-82.
125. Atchison CR, West AB, Balakumaran A, et al. Drug enterocyte adducts: possible causal factor for diclofenac enteropathy in rats. Gastroenterology 2000;119:1537-47.
126. Worrall S, Dickinson RG. Rat serum albumin modified by diflunisal acyl glucuronide is immunogenic in rats. Life Sci 1995;56:1921-30.
127. Kretz-Rommel A, Boelsterli UA. Cytotoxic activity of T cells and non-T cells from diclofenac-immunized mice against cultured syngeneic hepatocytes exposed to diclofenac. Hepatology 1995;22:213-22.
128. Bougie D, Johnson ST, Weitekamp LA, et al. Sensitivity to a metabolite of diclofenac as a cause of acute immune hemolytic anemia. Blood 1997;90:407-13.
129. Jurgensen JS, Seltsam A, Jorres A. Fatal acute diclofenac-induced immune hemolytic anemia. Ann Hematol 2001;80:440-2.
130. Angeles ML, Reid ME, Yacob UA, et al. Sulindac-induced immune hemolytic anemia. Transfusion 1994;34:255-8.
131. Cunha PD, Lord RS, Johnson ST, et al. Immune hemolytic anemia caused by sensitivity to a metabolite of etodolac, a nonsteroidal anti-inflammatory drug. Transfusion 2000;40:663-8.
132. Shirey RS, Morton SJ, Lawton KB, et al. Fenoprofen-induced immune hemolysis. Difficulties in diagnosis and complications in compatibility testing. Am J Clin Pathol 1988;89:410-4.
133. Bougie D, Aster R. Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen. Blood 2001;97:3846-50.
134. Hess DA, Rieder MJ. The role of reactive drug metabolites in immune-mediated adverse drug reactions. Ann Pharmacother 1997;31:1378-87.
135. Pirmohamed M, Breckenridge AM, Kitteringham NR, et al. Adverse drug reactions. BMJ 1998;316:1295-8.
136. el Mouelhi M, Ruelius HW, Fenselau C, et al. Species-dependent enantioselective glucuronidation of three 2-arylpropionic acids. Naproxen, ibuprofen, and benoxaprofen. Drug Metab Dispos 1987;15:767-72.
137. Spahn H. Assay method for product formation in in vitro enzyme kinetic studies of uridine diphosphate glucuronyltransferases: 2-arylpropionic acid enantiomers. J Chromatogr 1988;430:368-75.
138. Spahn H, Iwakawa S, Lin ET, et al. Procedures to characterize in vivo and in vitro enantioselective glucuronidation properly: studies with benoxaprofen glucuronides. Pharm Res 1989;6:125-32.
139. Iwakawa S, Suganuma T, Lee SF, et al. Direct determination of diastereomeric carprofen glucuronides in human plasma and urine and preliminary measurements of stereoselective metabolic and renal elimination after oral administration of carprofen in man. Drug Metab Dispos 1989;17:414-9.
140. Faed EM, McQueen EG. Separation of two conjugates of clofibric acid (CPIB) found in the urine of subjects taking clofibrate. Clin Exp Pharmacol Physiol 1978;5:195-8.
141. Mojarrabi B, Mackenzie PI. The human UDP glucuronosyltransferase, UGT1A10, glucuronidates mycophenolic acid. Biochem Biophys Res Commun 1997;238:775-8.
142. Hignite CE, Tschanz C, Lemons S, et al. Glucuronic acid conjugates of clofibrate: four isomeric structures. Life Sci 1981;28:2077-81.
143. Vree TB, van Ewijk-Beneken Kolmer EW, Verwey-van Wissen CP, et al. Direct gradient reversed-phase high-performance liquid chromatographic determination of salicylic acid, with the corresponding glycine and glucuronide conjugates in human plasma and urine. J Chromatogr 1994;652:161-70.
144. Grubb NG, Rudy DW, Hall SD. Stereoselective high-performance liquid chromatographic analysis of ketoprofen and its acyl glucuronides in chronic renal insufficiency. J Chromatogr B Biomed Appl 1996;678:237-44.
145. Loewen GR, Macdonald JI, Verbeeck RK. High-performance liquid chromatographic method for the simultaneous quantitation of diflunisal and its glucuronide and sulfate conjugates in human urine. J Pharm Sci 1989;78:250-5.
146. Hermening A, Grafe AK, Baktir G, et al. Gemfibrozil and its oxidative metabolites: quantification of aglycones, acyl glucuronides, and covalent adducts in samples from preclinical and clinical kinetic studies. J Chromatogr B Biomed Sci Appl 2000;741:129-44.
147. Liu JH, Smith PC. Direct analysis of salicylic acid, salicyl acyl glucuronide, salicyluric acid and gentisic acid in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1996;675:61-70.
148. Andersen JV, Hansen SH. Simultaneous quantitative determination of naproxen, its metabolite 6-O-desmethylnaproxen and their five conjugates in plasma and urine samples by high-performance liquid chromatography on dynamically modified silica. J Chromatogr 1992;577:325-33.
149. Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CP. Determination of indomethacin, its metabolites and their glucuronides in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis. Preliminary pharmacokinetics and effect of probenecid. J Chromatogr 1993;616:271-82.
150. Castillo M, Smith PC. Direct determination of ibuprofen and ibuprofen acyl glucuronide in plasma by high-performance liquid chromatography using solid-phase extraction. J Chromatogr 1993;614:109-16.
151. Zhou S, Paxton JW, Tingle MD, et al. Determinaton of two major metabolites of the novel anti-tumor agent 5,6-dimethylxanthenone-4-acetic acid in hepatic microsomal incubations by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Appl 1999;734:129-36.
152. Shipkova M, Schütz E, Armstrong VW, et al. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem 2000;46:365-72.
153. Smith PC, Hasegawa J, Langendijk PN, et al. Stability of acyl glucuronides in blood, plasma, and urine: studies with zomepirac. Drug Metab Dispos 1985;13:110-2.
154. Hyneck ML, Munafo A, Benet LZ. Effect of pH on acyl migration and hydrolysis of tolmetin glucuronide. Drug Metab Dispos 1988;16:322-4.
155. Kristensen DB, Imamura K, Miyamoto, et al. Mass spectrometric approaches for the characterization of proteins on a hybrid quadrupole fime-of-flight (Q-TOF) mass spectrometer. Electrophoresis 2000;21:430-9.
156. Bienvenut WV, Deon C, Pasquarello C, et al. Matrix-assisted laser desorption/ionization-tandem mass spectrometry with high resolution and sensitivity for identification and characterization of proteins. Proteomics 2002;2:868-76.
157. Gygi SP, Aebersold R. Mass spectrometry and proteomics. Curr Opin Chem Biol 2000;4:489-94.
158. Volland C, Sun H, Dammeyer J, et al. Stereoselective degradation of the fenoprofen acyl glucuronide enantiomers and irreversible binding to plasma protein. Drug Metab Dispos 1991;19:1080-6.
159. van Breemen RB, Fenselau CC, Dulik DM. Activated phase II metabolites: comparison of alkylation by 1-O-acyl glucuronides and acyl sulfates. Adv Exp Med Biol 1986;197:423-9.
160. Cheng Z, Radominska-Pandya A, Tephly TR. Studies on the substrate specificity of human intestinal UDP-lucuronosyltransferases 1A8 and 1A10. Drug Metab Dispos 1999;27:1165-70.